To test this hypothesis, we conducted a phase 1b, biomarker-driven trial, evaluating DNMT and HDAC inhibitors alone or in combination in sensitizing MMRp CRC to anti-PD1 therapy. Here, HDAC9 is linked to colorectal carcinoma.